Roche Paying $390m Up Front For Fibrosis-Fighting Promedior
The deal, which includes up to $1bn for milestones, gives Roche Promedior’s PRM-151, a Phase III-ready asset for IPF that has also completed a Phase II study in myelofibrosis and could be effective in a broad range of fibrotic diseases.
You may also be interested in...
While Vertex appears to have the cystic fibrosis market covered with its CFTR modulators, Enterprise has been exploring another channel, TMEM16A, in the hope of developing compounds that could possibly be used by everybody with the lethal genetic disease.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
Business development execs Patrick Schleck and Michael Crowley talk to Scrip about the company’s recent deals with Parvus, Jecure and Microbiotica in the inflammatory and autoimmune disease space.